Retatrutide Phase 3 Trial Targets Type 2 Diabetes with Kidney Impairment

Type 2 Diabetes is a chronic metabolic disorder characterized by high blood sugar, often leading to severe complications like renal impairment (kidney damage). Many patients struggle to achieve adequate glycemic control even with existing treatments like basal insulin, often combined with metformin and/or SGLT2 inhibitors. This study addresses the urgent need for more effective and safer therapeutic options for this vulnerable population with advanced disease, particularly those with moderate or severe kidney issues.

As an ACTIVE_NOT_RECRUITING study that commenced on March 15, 2024, with an estimated completion date in November 2026, no actual efficacy or safety results are currently available. The primary objective of this trial is to determine if Retatrutide can achieve a statistically significant improvement in glycemic control (measured by HbA1c reduction) and demonstrate a favorable safety and tolerability profile when compared to placebo in this specific, high-risk patient population. Researchers will meticulously assess changes in HbA1c, fasting plasma glucose, body weight, and various renal function markers (like eGFR) to understand the full therapeutic potential. The study's overarching goal is to establish the efficacy and safety of Retatrutide as a novel therapeutic option for Type 2 Diabetes patients experiencing moderate or severe renal impairment, who are already receiving basal insulin therapy.